Literature DB >> 2470647

Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

M J Selby1, E S Bain, P A Luciw, B M Peterlin.   

Abstract

The human immunodeficiency virus (HIV-1)-encoded trans-activator (tat) increases HIV gene expression and replication. Previously, we demonstrated that tat facilitates elongation of transcription through the HIV-1 long terminal repeat (LTR) and that short transcripts corresponding to prematurely terminated RNA are released and accumulate in the absence of tat. Here, using a transient expression assay, we tested clustered and compensatory mutations, as well as 3' deletions, in the trans-acting responsive region (tar) and observed that the primary sequence in the loop and secondary structure in the stem of the stem-loop in tar are required for trans-activation by tat. Insertions in the 5' region of tar revealed that tar must be near the site of HIV-1 initiation of transcription for trans-activation by tat. Deletions (3') and an insertion in tar demonstrated that an intact stem-loop is required for the recovery of prematurely terminated transcripts. Short and full-length transcripts were observed also with HIV type 2 (HIV-2) in the absence and presence of tat, respectively. We conclude that an intact stem-loop in tar is essential for trans-activation by tat and that initiation of transcription by HIV-1 promoter factors and elongation of transcription by tat are coupled.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470647     DOI: 10.1101/gad.3.4.547

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  171 in total

1.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  An adenosine at position 27 in the human immunodeficiency virus type 1 trans-activation response element is not critical for transcriptional or translational activation by Tat.

Authors:  A D Blanchard; R Powell; M Braddock; A J Kingsman; S M Kingsman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription.

Authors:  Fabien Darfeuille; Andrey Arzumanov; Sergei Gryaznov; Michael J Gait; Carmelo Di Primo; Jean-Jacques Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

7.  Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.

Authors:  B Elangovan; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 8.  Transcriptional and posttranscriptional regulation of HIV-1 gene expression.

Authors:  Jonathan Karn; C Martin Stoltzfus
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

9.  Structural analysis of wild-type and mutant human immunodeficiency virus type 1 Tat proteins.

Authors:  A P Rice; F Carlotti
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

10.  Functional analysis of the Tat trans activator of human immunodeficiency virus type 2.

Authors:  R Fenrick; M H Malim; J Hauber; S Y Le; J Maizel; B R Cullen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.